Shots:

• The company highlights its lead candidate- SLN360 for CV disease associated with high Lp (a) levels and has received the US FDA’s IND approval to start dose-escalation studies in healthy volunteers and secondary prevention patients with elevated Lp(a). The company plans to start dosing healthy volunteers in the P-I study later this year
• The company reveals that it has initiated a P-I study of SLN124 in 24 healthy volunteers for beta-thalassemia and MDS- marking the first dose of a Silence’s siRNA therapeutic delivered to humans using the GalNAc-siRNA platform. SLN124 has received the US FDA’s & EMA’s ODD for adult beta-thalassemia and FDA’s ODD for MDS and RPD for beta-thalassemia
• Silence received $2M milestones for commencing its work on the second target being explored under its complement pathway RNAi collaboration with Mallinckrodt and is eligible to receive additional $2M milestones if work commences on a third target in the collaboration

­ Ref: Silence Therapeutics | Image: The Pharma Letter